

Product Datasheet

COVID-19 & SARS-CoV S glycoprotein antibody (orb758975)

Description

Human monoclonal antibody to COVID-

Species/Host	Human
Reactivity	Virus
Conjugation	Unconjugated
Tested Applications	ELISA, IF
Immunogen	The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Target	COVID-19 & SARS-CoV S glycoprotein
Preservatives	PBS with 0.02% Proclin 300.
Concentration	1 mg/ml
Storage	Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
Note	For research use only
Application notes	This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of

Biorbyt Ltd.

7 Signet Court, Swann's Road, Cambridge, CB5 8LA, United Kingdom

Email: info@biorbyt.com | Phone: +44 (0) 1223 859-353 | Fax: +44 (0)1223 280 240

Biorbyt LLC.

68 TW Alexander Drive
Research Triangle Park
Durham, North Carolina
27709, United States

Email: info@biorbyt.com | Phone: +1 (415) 906-5211 | Fax: +1 (415) 651-8558